This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Dysmenorrhea

This study has been completed.
Information provided by:
Nobelpharma Identifier:
First received: September 13, 2005
Last updated: September 6, 2010
Last verified: September 2010
The purpose of this study is to determine whether combination oral contraceptive pill of Norethindrone & Ethinyl estradiol is effective in the treatment of dysmenorrhea associated with endometriosis.

Condition Intervention Phase
Dysmenorrhea Drug: Norethisterone,Ethinylestradiol Drug: Sugar pill Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 3,Placebo Controlled,Randomized,Double-Blinded,NSAID-Add-on,Clinical Trial of Mono-phase Low Dose Oral Contraceptive Pill for Treatment of Dysmenorrhea Associated With Endometriosis.

Resource links provided by NLM:

Further study details as provided by Nobelpharma:

Primary Outcome Measures:
  • patient response to treatment for dysmenorrhea associated with endometriosis,as evaluated by VRS

Secondary Outcome Measures:
  • changes in the VAS of dysmenorrhea.
  • changes in the VRS of non-menstrual pain.
  • changes in the VAS of non-menstrual pain.
  • changes in the clinical evaluation of pelvic induration.
  • changes in the size of ovarian endometrioma.

Enrollment: 100
Study Start Date: December 2004
Study Completion Date: March 2006
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Norethisterone,Ethinylestradiol Drug: Norethisterone,Ethinylestradiol
Placebo Comparator: Sugar pill Drug: Sugar pill


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • dysmenorrhea associated with endometriosis

Exclusion Criteria:

  • severe hepatopathy
  • pregnant woman
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00212342

Sponsors and Collaborators
Study Director: Naoki Terakawa, M.D.,Ph.D. Tottori University,Tottori,Japan
  More Information Identifier: NCT00212342     History of Changes
Other Study ID Numbers: IKH-01-4
Study First Received: September 13, 2005
Last Updated: September 6, 2010

Additional relevant MeSH terms:
Menstruation Disturbances
Pathologic Processes
Pelvic Pain
Neurologic Manifestations
Signs and Symptoms
Contraceptive Agents
Norethindrone acetate
Contraceptives, Oral
Ethinyl Estradiol
Contraceptives, Oral, Combined
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptive Agents, Female
Hormones, Hormone Substitutes, and Hormone Antagonists
Contraceptives, Oral, Synthetic processed this record on September 21, 2017